Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Fase II-onderzoek naar oncolytisch coxsackievirus A21 bij niet-resectabel melanoom
nov 2021 | Dermato-oncologie